(NASDAQ: AMPH) Amphastar Pharmaceuticals's forecast annual revenue growth rate of 5.01% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.54%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.75%.
Amphastar Pharmaceuticals's revenue in 2026 is $720,530,000.On average, 9 Wall Street analysts forecast AMPH's revenue for 2026 to be $33,585,135,473, with the lowest AMPH revenue forecast at $31,570,089,075, and the highest AMPH revenue forecast at $35,155,284,319. On average, 9 Wall Street analysts forecast AMPH's revenue for 2027 to be $35,460,407,318, with the lowest AMPH revenue forecast at $32,511,913,825, and the highest AMPH revenue forecast at $37,825,551,493.
In 2028, AMPH is forecast to generate $36,669,876,086 in revenue, with the lowest revenue forecast at $33,402,149,859 and the highest revenue forecast at $39,584,418,032.